CLOs on the Move

DTx Pharma

www.dtxpharma.com

 
DTx Pharma is a San Diego based startup with a novel technology for delivery of RNA medicines.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Olink Proteomics

Thoroughly validated, rapid, high-throughput multiplexed assays for protein biomarker discovery - high specificity & minimal sample volume requirements

Transgene

Transgene SA is a France-based fully integrated biopharmaceutical company specialising in immunotherapeutics to treat cancer and infectious diseases. The company has subsidiaries in China and in the USA.

Complexa Inc

Complexa is a clinical stage biopharmaceutical company focused on transforming the treatment of fibrosis and inflammation-associated orphan diseases. Leveraging its differentiated endogenous nitrated fatty acid cell signaling technology, Complexa is advancing a platform of agents which target fibrosis and inflammation across multiple orphan disease indications.

Nkmax

NKMax America is harnessing the power of the body`s immune system through the development of unique Natural Killer (NK) cell therapies. NK cell adoptive immunotherapy enhances a patient`s ability to destroy abnormal cells.

Minaris Advanced Therapies

Minaris Regenerative Medicine is a global Contract Development and Manufacturing Organization (CDMO) with over 25 years of experience in cell and gene therapies. The company operates advanced facilities across North America, Europe, and Asia, providing comprehensive solutions for advanced therapy medicinal products (ATMPs). Minaris specializes in clinical and commercial manufacturing, process development, and technology transfer, ensuring compliance with regulatory standards in the U.S., EU, and Japan. The company offers a range of services, including GMP manufacturing for cell therapies, technology transfer, and clinical development support for Phase I-III trials. Minaris has successfully completed over 100 technology transfers and has recently commercialized LYFGENIA, a gene therapy for sickle cell disease. With a focus on collaboration, Minaris serves over 180 biotech and pharmaceutical clients, providing tailored solutions for their specific needs in regenerative medicine. Its facilities include expanded cleanroom capacity and analytical labs to support large-scale production.